Obermatt
See Similar Stocks →

Definium Therapeutics

NSQ:DFTX · CA24477V1058
PharmaceuticalsSmall

360° View

22
Price/Sales—
Price/Earnings83
Price/Book3
Dividend Yield1
Revenue Growth—
Profit Growth11
Capital Growth21
TSR 52w88
Leverage40
Liquidity25
Refinancing28
Combined9
Analyst Opinions66
Pro Holdings75
Opinion Changes50
Market Pulse16

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Employees34
Websitedefiniumtx.com
ISINCA24477V1058
Last UpdateApr 2, 2026
Index & Theme
NeurologyDigital Mental HealthPsychiatryAddictionNeurosciencePain ManagementCentral Nervous SystemPsychedelic-Based TherapyBiotechnologyHealth CareMedicalPharmaceutical

Description

Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The company is developing a pipeline of innovative product candidates targeting neurotransmitter path…

Analysis

Definium Therapeutics's 360° View rank of 22 places it among the weakest overall — better than 22% of its true peers.

It's growing slowly (40) and on the expensive side (33). On safety it is highly leveraged (10), and the market shows favorable sentiment (59). Taken together, its Combined rank of 9 reads as among the weakest overall.

360° rank · history

1007550250
22
2026

All-time high

31

Mar 2026

All-time low

22

Jun 2026

Average rank

27

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
—
—
—
—
Price/Earnings
83
—
—
—
Price/Book
3
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
33
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Definium Therapeutics with its peers
NRX Pharmaceuticals
NAQ:NRXP
49
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
EyePoint
NMQ:EYPT
34
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Axsome Therapeutics
NMQ:AXSM
43
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Edgewise Therapeutics
NSQ:EWTX
49
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cybin
NEO:HELP
—
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cresco Labs
CNX:CL
43
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →